Home/ Stocks/ ALDX

Aldeyra Therapeutics, Inc.

ALDX XNAS

$1.55 -0.05 (-3.14%) ▼ 15-min delayed

Open

$1.56

High

$1.61

Low

$1.52

Volume

1.17M

Market Cap

$95.91M

About Aldeyra Therapeutics, Inc.

Aldeyra Therapeutics Inc is a biotechnology company engaged in developing and commercializing next-generation medicines to improve the lives of patients with immune-mediated and metabolic diseases. The company's product candidate, Reproxalap, is a treatment in late-stage development for dry eye disease and allergic conjunctivitis. In addition, it also has additional product candidates in development for proliferative vitreoretinopathy, primary vitreoretinal lymphoma, and other retinal diseases, autoimmune disease, and cancer. Company products includes ADX248, ADX743, ADX631, ADX246, ADX629, ADX2191.

Sector: PHARMACEUTICAL PREPARATIONS Employees: 7 Website →

Key Financials

Period	Revenue	Net Income	EPS
Q1 2026	N/A	$-3,452,619	$-0.06
FY 2025	N/A	$-33,846,661	$-0.56
Q3 2025	N/A	$-7,688,341	$-0.13
Q2 2025	N/A	$-9,767,312	$-0.16

Earnings & Analyst Ratings

Next Earnings: Mon, Nov 2, 2026

Calendar →

Related Market News

No specific coverage for ALDX yet. Check out our latest market news or earnings calendar.

Get ALDX Alerts

Stay ahead with breaking news, price alerts, and expert analysis on Aldeyra Therapeutics, Inc..

Disclaimer: This page is for informational purposes only. Stock data is delayed by at least 15 minutes. Always conduct your own research and consult with a qualified financial advisor before making investment decisions.